Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Aclaris Therapeutics Inc (NASDAQ: ACRS) closed at $2.3 up 7.98% from its previous closing price of $2.13. In other words, the price has increased by $7.98 from its previous closing price. On the day, 0.97 million shares were traded. ACRS stock price reached its highest trading level at $2.34 during the session, while it also had its lowest trading level at $2.1.
Ratios:
For a deeper understanding of Aclaris Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.92 and its Current Ratio is at 3.92. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 28, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 19 ’24 when Mehra Anand bought 666,666 shares for $2.25 per share. The transaction valued at 1,499,998 led to the insider holds 710,030 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACRS now has a Market Capitalization of 249194048 and an Enterprise Value of 155526048. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.83 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 9.88 whereas that against EBITDA is -2.366.
Stock Price History:
The Beta on a monthly basis for ACRS is 0.66, which has changed by -0.12704921 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, ACRS has reached a high of $5.17, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 11.62%, while the 200-Day Moving Average is calculated to be 32.52%.
Shares Statistics:
For the past three months, ACRS has traded an average of 1.14M shares per day and 1564160 over the past ten days. A total of 108.34M shares are outstanding, with a floating share count of 92.31M. Insiders hold about 14.80% of the company’s shares, while institutions hold 73.39% stake in the company. Shares short for ACRS as of 1761868800 were 4233762 with a Short Ratio of 4.12, compared to 1759190400 on 5550615. Therefore, it implies a Short% of Shares Outstanding of 4233762 and a Short% of Float of 4.66.
Earnings Estimates
A detailed examination of Aclaris Therapeutics Inc (ACRS) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.29 and -$0.54 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.57, with 6.0 analysts recommending between -$0.3 and -$0.87.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $1.1M this quarter.It ranges from a high estimate of $1.2M to a low estimate of $1M. As of. The current estimate, Aclaris Therapeutics Inc’s year-ago sales were $9.21MFor the next quarter, 2 analysts are estimating revenue of $1.73M. There is a high estimate of $2.4M for the next quarter, whereas the lowest estimate is $1M.
A total of 3 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $8.8M, while the lowest revenue estimate was $7.5M, resulting in an average revenue estimate of $8.03M. In the same quarter a year ago, actual revenue was $18.72MBased on 8 analysts’ estimates, the company’s revenue will be $4.93M in the next fiscal year. The high estimate is $10M and the low estimate is $900k.
